afternoon XXXX Good Daré to year-end our Thank results and and XX, financial for business December you. welcome update Bioscience. call
XXXX. results, milestones believe last impactful some today our review use and our plan to disproportionately including discuss and anticipated women's to year development important why health strategy, we efficient Our the time highlight since in objectives in call is our in business November investment and and to full review is
historical begin, to within discussion meaning which or like considered we the statements. will Litigation Act unknown implied include the known of statements laws Private made today's during risks Before could this you events that by to of uncertainties. call those Reform of to of I'd should Actual these forward-looking facts remind that anticipated securities harbor pursuant forward-looking results and the are materially and XXXX. provisions Securities safe Any statements are from statements differ due or statements be not made federal
should on forward-looking place reliance You statements. undue not
entirety was are on the the statements ended for Form their XXXX annual company's by including in qualified the XX-K cautionary statements report XX, December year filed SEC filings, today. Forward-looking which in our
reflect undertakes point Daré also information no is includes or time-sensitive obligation law. current as content update I'd information new to required out XXXX. call, of except to like forward-looking that March developments today, only the that this to statements XX, by call after as this any of
received one pivotal study our monthly disorder we to required top this a which the Phase rights candidate XACIATO X positive license FDA-approved enrollment case, believe female commence IIb second that I/II time We secured ring Sildenafil completed atrophy collaboration Phase candidate, commercial announced symptoms came vaginal with for hormone hormone-free treatment FDA in our hormone-free study one vasomotor our single in Bayer. what menopause, our with to and product, to Ovaprene, DARE-VVAX; XX-day be study announced the therapy we in had our under our we vaginal Cream DARE-HRTX. acceptance our will for XXXX and line agreement for the contraceptive we readouts, By Organon. We close, for sexual arousal for candidate, commercial
in objectives accomplishments I just additional that look to us XXXX clinical identified regulatory milestones position shortly. XXXX as related These other milestones sharing candidates programs the And well to commercialization, to I portfolio XXXX, not but potentially well. only our forward include and in achieve to
following on women's Daré focused companies. know pharmaceutical in With we that and our independent deepest health of the Those global been other candidates we product pipeline company, development of solely knowledge, including who any to squarely candidates XX are have, have stand-alone portfolio, our women's stage health.
And It of $XXX has on X% that up XXXX based is as research blockbuster revenue generated products those yet, care And a by conditions invested to health as over generate been in sales. IQVIA a women's contribute blockbuster make for in that those health reported female-specific XXXX, products products of million the XX% annual products. oncology. all in mere beyond data XX%
that and those can potentially our contraceptive, on our our are our women, of an analogous candidate value the particularly candidates dysfunction product to in a menopause impactful arousal which individual candidates in We over like women odds given more there brand, health even the $X of men. erectile XX health program the disorder Thus, FDA-approved all for women's seen yet condition potential of our love our most health we billion development and $X cinemas the including sexual shortly. in number a with the would of is since have portfolio, program, sexual for statistics, be in generating Sildenafil over billion investment, and Cream, shareholders represent categories, stage first to given product and in disproportionately
many So only as they importantly, effective set the such, the not options. lacking for about and convenient investing or care partners those family it is therapeutic broad And our health, belief women women's the health that for for members including of category. prioritizing good stakeholders, also women's but is in
health, to indications because to contraception, market, Our we vaginal are current have we could where these bring We be or areas given first-in-category saw the in a efforts sexual innovation first-line health product innovation opportunities category. focused therapeutic menopause, develop chose women in in health, fertility. and to first a product reproductive new
our have in we to investment that single portfolio, every on individual stand to importantly, while portfolio a its So candidate. justify product our in broad has merits product candidate own
select candidate determination development, Specifically, a for strict a before we we meets new the criteria. it that make
First, the persistent a need. of product a market in candidate meaningful unmet has to opportunity form the address
Second, it be category has both. to line have potential in or or the first first to
the and by care differentiated of clearly proof product deliver which a measured ideally use ingredients cost it ultimately to demonstrated have well-characterized and by label gate which time, active pharmaceutical already is And development pull-through. over as market outcomes even committed clear and risk. represent and critical should evidenced a and opportunity it an concept finally, Third, standard improvement access is should clinical of patient for acceptability
and programs and potentially X XXXX innovation than differentiated more shortly, women's Our III With FDA-approved XX in Phase health health discuss events X development, in distinct product we milestone resulted transformational candidates with that collaborations development-stage X in or focused indications. X will XACIATO. nearing anticipated efforts across transformative commercialization, women's in to X leaders have Organon deliver Bayer in product
anticipated you milestones. our XXXX to results and key now with want Daré's XXXX milestones and share I
morning XXXX encourage to issued it press review you read our release of In remarks, since to a addition comprehensive this accomplishments. provides more my I our
Ovaprene, We DARE-VVAX, Cream, Sildenafil have important XACIATO, and DARE-HRTX upcoming for milestones DARE-DPMX.
to focus primarily comments going those on I'm today programs. So my
gel clindamycin me highlighting with Organon global X%. vaginal So of the that phosphate by begin commercialization let our agreement license supports XACIATO,
vaginal patients XX and bacterial States. female in United age lencostamide XACIATO of in treatment reminder, the years is administration single-dose a of for older As antibacterial vaginosis for the a indicated
condition Bacterial and approximately is most U.S. the story in vaginosis million of common our is of XX XACIATO women affect strategy. candidate The age, great vaginal in to a reproductive alone. portfolio women by available estimated validation a development women could we the a option. of yet on underserved products. hoped novel and number been currently user by that focusing We overall experience, But have with condition outcomes her improving deliver selection
to data And a so, could drives the collaboration to create commercialization the III value, study drive generate the labeling. Understanding value. to stroke by differentiation that design for the necessary support target a opportunity we Phase doing
out that XACIATO leverage launching accelerate the established thrilled are of focused and they Nexpenon will is that Organon, We women's Merck team their to sales spin uptake. health XACIATO
are manufacturing excited the the with support health at to the category activities commercial completed, launch in of nearly pharmaceutical women's since Specifically, validation Organon, now Merck. product activities preparation launch underway first what spinning into commercial about out required for will Organon's the launch be we
launch, Given providers track access. with roughly that John more provides on treatment to of that patterns. second activity The from care sales health commercial team sales before that record first end commercial Nexplanon the has XX% the these XACIATO update. XACIATO on will team when demonstrated. We success immediate the Nexplanon we those sale based of be and who strong to our the commercial is anticipate there prescribe has targets expect overlap the believes quarter, for enable a his XACIATO providers team benefit to leveraged the the of are expected viable relationships the Organon
as required to investigational In whose Bayer. terms program, study important registration. contraceptive, license it the potential allows hormone-free, acceptance of single is Ovaprene last commence support believe year milestone agreement for to clinical commercial for submission monthly an the the pivotal the of a was PMA around Ovaprene we first-in-category what our program, intravaginal FDA's IDE with our be Ovaprene will rights us our
under pivotal We clinical of December, The our collaborative brought to of our pivotal in investigators study PMA October announced an belief a sufficient FDA. study IDE and having meeting. submission will subjects division support network. together NIH's XXXX mental agreement, duration NICHD's in The being from the trial CRADA, pivotal confirmed research NICHD for development will or target approximately conducted approval NICHD be the around for and investigator the that single study with by a FDA sites complete, months cycles XXX those a contraceptive with the XX And planned to XX to study is XXX and use.
We anticipate the initiation recruitment in subject pivotal Phase of XXXX. III middle of
XACIATO Ovaprene So innovative one and that's Bayer. and with and Organon X with one X collaborations, brands, transformational potentially
X.X% programs. let's completely for Well, our premium the listen with a in begin create So a potential what's product to women's health. to novel candidate unpartnered category Daré next on
FSAD. that of and are of to We general female physical arousal lack disorder, sexual or address associated are arousal the looking hallmark the distress response and sensations the
as Phase wanted analogous what we terms upfront, you can line exploratory quite pharmacology pathophysiology completed approach mentioned size. erectile both in comparable men, to I in sense enrollment XXXX. give for also As of We FSAD or IIb XXXX, are well readout And study as you our is dysfunction the top the data we Phase second as in the and to IIb quarter in a of in projected expect. target ED addressable markets of
refresher, ingredient the Sildenafil increased that demonstrated flow previously cream to conducted as Daré is active this external Viagra, temperature First, way internal of the an assessed in its tissue. sensing by genital vaginal of by SST, same of our activity These the studies licensor, data probe formulation which the when in an and proof blood and when target both camera. formulation tissue, that via be concept assessed to is achieving the female provide
general endpoints Obviously, to order IIb referred the forward reported performance program. in exploratory into their appropriate vaginal sensors about patient-reported to designed potential III practical number identify program. and study questions take different setting, the to not a as was improvements probes Sildenafil outcomes Phase women genital patient at-home the outcomes the evaluate to III and in Phase evaluate Cream of for and ask to a ways and of sensations temperature to are Thus, select Phase
line will, top and will study the regarding when reporting population the report have from a patient the a the top study results, first bring the to Therefore, we in exploratory endpoints study, proposals as evaluate we Phase step, set data the assessment we of tools for we we subsequent line data the study IIb utilized the a in our as to to and program. our conclusion, to the number III to full Phase FDA formalize
to solution to women United in distressed or are option no XX goal their address condition and estimated bring to much-needed for low treatment seek the who a and alone no to the arousal million product be today. is FDA-approved States Our sexual
completed DARE-VVAX, for wholly both to another Third, line of I/II the I'd Australian the studies were subsidiary. results owned last DARE-HRTX through Phase year, highlight X and which for our top positive from like conducted one
study of therapy for of a vasomotor I/II menopause, Phase let's symptoms So the DARE-HRTX, menopausal VMS. start of the with first or the treatment hormone
you Fortunately, question, Astellas's many in flashes. you answer reminding and of commonly probably what Super as menopause be vasomotor may VMS. ad challenging to it Bowl is the watched worth saw symptoms referred are VMS But for stands hot which that to the people
in XX it's category, U.S. million or be Super a approaching was year With in the the brand women the subject Bowl of having annual and revenue, generated that each ad. with $X a over the in to not menopause surprising legacy condition estimated in in billion
are delivering the product to be first-in-category has vasomotor combination condition? Well, potential menopause. what developing of So we symptoms hormone for treatment the convenient in the the for DARE=HRTX vaginal monthly a
this bioidentical estradiol through Specifically, XX DARHRTX is release bioidentical and intervaginal an to ring days. progesterone investigational designed vaginal ring over
or shown fracture. American administration. routes bone hormone postmenopausal XXXX position and North therapy format the monthly with IBR. the Hormone bioidentical of FDA-approved statement has supports may therapy also for and to women DARE-HRTX oral offer no hormones. treatment menopause hormones and the in with are that Society, over been nonoral therapy vasomotor of effective to observes genitourinary routes monthly NAMS, both symptoms The the product has NAMS hormone be remains the So first and nondaily, of and loss There menopause peri both nonoral and potential most prevent advantages X Menopause the options syndrome
We that dose levels that XX or were over for weeks DARE-HRTX Phase of released reported, combinations the hormone of dose the both higher healthy line data therapy. from of targeted achieved X DARE-HRTX different the top I/II previously and announced use levels from in the postmenopausal study of as formulation estradiol exceeded the of And women. lower XX approximately we
released X.X compared evaluated estradiol than ring. and despite addition, formulation PH In BMS maturation menopause levels P These the potential level. of effective in the vaginal and higher vaginal size, sample in hormone at in to genitourinary study lower as small the convenient index, of therapy the from XX-day to and statistically as achieved symptoms baseline all the well significant dose a DARE-HRTX data the of less both improvement the support deliver
the data FDA's pathway clinical we to pathway approval XACIATO. pedestrone efficacy of DAIR-AXTX development, safety ingredients leverage in same and that's marketing for and estradiol active existing that Following intend DARE-HRTX, we XXX(b)(X) to on utilize use in to specifically the the the the XXX(b)(X), that pathway U.S., obtain
FDA between PK due women vasomotor of top justified that trial with symptoms basically DARE-HRTX placebo-controlled via and study, data progesterone DAER-HRTX and a clinical and approval Phase approval seek FDA I/II the selected the trial PK indication drugs. with estradiol relative menopause XXX(b) pre-IND achievable single communications Phase treatment via moderate-to-severe for to believe and intend III FDA of is DARE-HRTX We bioavailability Based in DARE-HRTX of from of listed scientifically intact or by DARE-HRTX the that to uterine. on the supported bridge the line pharmacokinetic for a pathway we
IND support directly Phase III to continue that providing planned this IND and support updates single look on the We activities time the the Phase therefore III Phase study. the III progress opening lines these submission study further pressing year. into to as support to forward to activities nonclinical include and Ongoing manufacturing to studies registration, to
vaginal vulvar tamoxifen first Australia history a X DARE-VVAX VVA. category XX% to I/II U.S. estimated women labeled cases. in breast Phase currently that is of treatment and conducted proprietary or study It's atrophy, invasive for cancer. more hormone-free use safe the an in for potential formulation was be hormone the breast in receptor million intravaginal DARE-VVAX receptor vaginal administration. as treatment for no FDA-approved DARE-VVAX, our second than vaginal hormone Approximately investigational in positive are have hormone-free the of candidate. The are cancer. There positive has for atrophy products
XX% associated symptoms, as lead women for contraindicated with patients rates use breast not These survivors candidates intercourse form often can are hormone therapies generally painful estimated estrogen their is is to in prevalent atrophy to which and in despite cancer receptor VVA distress at and cancer breast vaginal interpersonal postmenopausal hormone-containing survivor. for the any positive XX%. of
a In vaginal in treatment and I/II demonstrated the is XXXX, unmet So positive for clear nonhormonal of November study, need line ongoing And DARE-VVAX development. our Phase there study symptoms VVA. medical of of supporting from effective for announced we the in bothersome DARE-VVAX. that top parameters an VVA improvement results cytology
to Following active XXX(b)(X) and development, U.S. existing the DARE-VVAX marketing to similarly we clinical of DARE-VVAX in intend the obtain leverage and pathway in ingredient safety efficacy the FDA's data again, the to tamoxifen utilize approval on
provide continue on year, we with time engage additional this the line to updates to IND FDA II. Phase the As the we'll process on
initiated hydrogel NSAD primary Phase also of our DARE-PDMX data a Last year investigational proprietary the year. top formulation, cramps development this this We that to is is our candidate formulation like and Australia DARE-PDMX, study XACIATO. used expected treat line menstrual I'd to delivering same product dysmenorrhea, are by the highlight in in vaginally, or technology utilizing diclofenac I
of dysmenorrhea $XX this as and Primary menstrual valued the normal pain menstruation in market $XX period. the XXXX estimated research dysmenorrhea women that size is to as market billion with before, painful pelvic XXXX. billion during cramping described suggested the is increase the expected be in to in global anatomy lower at treatment for is market abdomen defined to typically in Recent
to of reproductive Committee of absence College of dysmenorrhea short-term common is Obstetrics adolescent age. leading and and and American primary The common dysmenorrhea. adolescence Gynecologists range range Primary they school most a on rates begins adolescents but during and usually and girls it's cause the experiencing adolescent women to menstrual vary have According a girls young Healthcare, preference from most recurrent it [ph]. and adolescent XX% XX% symptom the
counter available contraceptives undesirable side relief effects. increased The number including adverse also most over nausea, side hormonal an of oral alterations may are of gastrointestinal for common hormonal NSAIDs which and temporary produce the vomiting, for contraceptives often include produce which events, painful effects, cause the NSAIDs bloating symptoms, a or oral can interventions risk undesirable can
treatment administration, seen diclofenac first-in-category the associated delivery condition oral the vaginal option with there leveraging by primary to at So provide options localized symptoms while are a pain-related side for can we effects with currently product, be oral of the has potential no the vaginal commonly a convenient treatment and dysmenorrhea, NSAIDs. diclofenac addresses commonly Because of medications. that may believe DARE-PDMX extend effects relief a in reduce a delivering minimizing we side the format that duration the vaginal pain FDA-approved
undergone identify be our I technology candidates of promising recently successful has of in platform savings can time development candidates unmet both hydrogel and in strategy to that cost. and opening leverage cost to part advantages time The review health. needs terms and Now meaningful testing my in and to could offer is and regulatory the ability that preclinical women's in comments, clinical new efficiently our of address noted developed that
that discussed hope platform, evaluated. which on It from DARE-PDMX not hydrogel use but already and benefit the of will development technology is the of closely that relies the I've our that DARE-LDTX been has similarly today
license turn now will John over in and of the overview XACIATO to have an to of place Ovaprene, I respectively. agreements X commercialization for we provide it
